Question:
How is tocilizumab for COVID-19 reported? Can we report it in an outpatient setting?
Answer:
Tocilizumab for COVID-19 has been approved for use in the inpatient setting only. The HCPCS code Q0249 (njection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg) is reported per 1 mg.
This question was answered in our Coding Essentials for Infusion & Injection Therapy Services. For more hot topics relating to infusion services, please visit our store or call us at 1.800.252.1578, ext. 2.